Source comparison
Thymosin Alpha-1 Versus Other Immunomodulatory Peptides: Research Comparison
Thymosin Alpha-1 TLR9 activation, T-cell maturation, dendritic cell priming 48–72 hours ↑ IFN-γ, IL-2, IL-12; minimal IL-6 $450–$800 per in vivo study Best choice for T-cell-focused immune studies; clean Th1 polarization without inflammatory noise. Proven in s
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR9 activation, T-cell maturation, dendritic cell priming
- 48–72 hours
- ↑ IFN-γ, IL-2, IL-12; minimal IL-6
- $450–$800 per in vivo study
- Best choice for T-cell-focused immune studies; clean Th1 polarization without inflammatory noise. Proven in sepsis and vaccine models.
- Thymosin Beta-4
- Actin sequestration, wound healing, anti-inflammatory
- 5–7 days
- ↓ TNF-α, IL-1β; ↑ IL-10
- $600–$1,100 per study
- Superior for tissue repair research; minimal direct T-cell effects. Not a first-line choice for adaptive immunity studies.
- LL-37 (Cathelicidin)
- Antimicrobial peptide, neutrophil recruitment
- 6–12 hours
- ↑ IL-8, TNF-α; broad inflammatory activation
- $350–$650 per study
- Excellent for innate immunity and infection models; poor specificity for adaptive immune research. High inflammatory background complicates T-cell assays.
- Epithalon
- Telomerase activation, neuroendocrine modulation
- 14–21 days
- Minimal direct cytokine modulation
- $500–$900 per study
- Unproven in immune modulation contexts; primary application is aging/longevity research. Limited peer-reviewed immune data.
- BPC-157
- Angiogenesis, VEGF upregulation, gastric protection
- 3–5 days
- ↑ VEGF; indirect immune effects via tissue healing
- $400–$750 per study
- Strong in wound healing and vascular research; indirect immune benefits only. Not a substitute for direct immunomodulators like Tα1.